

Remarks

Claims 3-6, 9-12, 17, 24 (new), 25 (new), 26 (new) and 27 (new) are pending in this application following amendments presented in this paper.

This second preliminary amendment is submitted in response to the Notification of Insufficient Fees dated March 26, 2007. It is stated in this Notification that a Preliminary Amendment has not been entered. Further, this Second Preliminary Amendment corrects the inadvertent inclusion of two claims number 18 through the cancellation of both claims number 18.

New Claim 24 is a combination of previous Claims 1, 7, 8, 13, 15 and 16. Additional amendments, such as the elimination of R^8 and its definition, have been made for clarity and consistency. For example, there is no R^8 variable in new Claim 24.

Similarly, new Claim 25 is a combination of previous Claims 2, 7, 8, 13, 15 and 16. Further, amendments have also been made for clarity and consistency as described above for new Claim 24.

New Claim 26 is based upon previous Claim 18 (first occurrence) having a single dependency rather than multiple dependency.

New Claim 27 is based upon previous Claim 18 (first occurrence) having a single dependency rather than multiple dependency and the dependency is from new Claim 24.

Clarifying amendments have been made to Claims 3, 4, 9, 10 and 17. The dependency of Claims 3-6 and 9-12 has been changed with the presentation of new Claims 24 and 25. The second occurrence of Claim 18 is cancelled consistent with an Article 34 Amendment made during the International Stage of the present application. Claim 17 is amended with the addition of the name of the compound of Example 19.

Applicants contend these amendments more clearly define the subject matter of the present invention. No new matter is believed to be added by new Claims 24, 25, 26 or any of the amendments presented.

Applicants respectfully request favorable consideration of their invention as claimed.

Respectfully submitted,

/ John C. Demeter/

John C. Demeter
Attorney for Applicant(s)
Registration No. 30,167
Phone: 317-276-3785

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

April 4, 2007